Compound Planning Inc. Buys 9,655 Shares of Astrazeneca Plc $AZN

Compound Planning Inc. lifted its stake in shares of Astrazeneca Plc (NYSE:AZN) by 29.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,583 shares of the company’s stock after buying an additional 9,655 shares during the period. Compound Planning Inc.’s holdings in Astrazeneca were worth $7,473,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of AZN. TD Asset Management Inc lifted its position in shares of Astrazeneca by 20.0% during the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares in the last quarter. AMG National Trust Bank boosted its holdings in shares of Astrazeneca by 20.4% in the third quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after acquiring an additional 7,289 shares during the period. US Bancorp DE grew its position in shares of Astrazeneca by 6.6% in the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after purchasing an additional 15,065 shares in the last quarter. Natixis Advisors LLC grew its position in shares of Astrazeneca by 14.3% in the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock valued at $161,142,000 after purchasing an additional 262,465 shares in the last quarter. Finally, Bleakley Financial Group LLC raised its stake in shares of Astrazeneca by 8.4% during the 3rd quarter. Bleakley Financial Group LLC now owns 79,983 shares of the company’s stock valued at $6,136,000 after purchasing an additional 6,172 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent research reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Trading Down 1.7%

Shares of AZN opened at $174.87 on Friday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a market capitalization of $271.20 billion, a P/E ratio of 26.26, a P/E/G ratio of 1.55 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm’s 50 day simple moving average is $187.22 and its 200 day simple moving average is $186.24.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.